New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic therapeutics, has been granted a U.S. patent for its drug candidate EB-002. The license, No. 11,945,778, issued by the United States Patent and Trademark Office, includes broad claims for treating brain neurological disorders.
生物技術公司Enveric Biosciences(納斯達克股票代碼:ENVB)專注於神經可塑性治療,其藥物候選Eb-002已獲得美國專利。美國專利和商標局頒發的第11,945,778號許可涵蓋了治療大腦神經疾病的廣泛要求。
This achievement enhances Enveric's intellectual property protection for EB-002, covering treatment methods for a variety of neurological conditions, including sleep disorders, depression, substance-related disorders and headaches. EB-002, a next-generation psilocin prodrug, is currently under development for neuropsychiatric disorders, initially focusing on anxiety.
這一成就增加了Enveric的知識產權保護,涵蓋了治療各種神經疾病,包括睡眠障礙、抑鬱症、物質相關疾病和頭痛等的治療方法。下一代賽洛昔芬前藥Eb-002目前正在開發用於神經精神類疾病,最初集中於焦慮症。
Significant Intellectual Property Milestone
重要的知識產權里程碑
Joseph Tucker, Ph.D., CEO of Enveric, emphasized the importance of this patent: "EB-002, the lead compound from Enveric's EVM201 screening program, now enjoys U.S. patent coverage under three issued patents. These include compositions and pharmaceutical formulations of EB-002 (US 11,707,447), methods of making the molecules (US 11,845,726), and now methods of treating a broad range of brain neurological disorders (US 11,945,778). PCT patent applications are also pending."
Enveric的首席執行官Joseph Tucker博士強調了這項專利的重要性:“Eb-002是Enveric的EVM201篩選計劃的主要化合物,現在已在三項已頒發的專利下獲得美國專利覆蓋範圍。其中包括Eb-002的組成和藥物配方(美國專利11,707,447),製造分子的方法(美國專利11,845,726)以及治療廣泛範圍的大腦神經疾病的方法(美國專利11,945,778)。有關此項專利的國際專利申請也正在等待批准。”
Dr. Tucker added, "Deploying comprehensive patent portfolios to protect lead drug development candidates helps to de-risk and accelerate clinical development, furthering the Company's efforts to rapidly bring this new drug to patients."
Tucker 博士補充道,“部署全面的專利組合,以保護主要藥物開發候選者,有助於降低風險,加速臨床開發,進一步推動公司爲病人快速引入這種新藥所做的努力。”
Cover image made with AI
封面圖片由人工智能製作